




Highlights of HCPWP involvement in EMA activities





Classified as public by the European Medicines Agens



What did we do?

Activities
Topics
Collaborations
Concepts
Initiatives



# Information on medicines: priority since the start

**EC** report on product information document SmPC **EMA** EPAR templates action plan PL HCPWP on product **e-PI** topic group: information SmPC information **Information** on medicines on vaccines Workshop: Medicines labelling communication **User testing** about medicines





## Evaluating & communicating benefit-risk

Geriatric medicines Risk communication

Workshop on methodologies for B/R evaluation

Pregnancy & breast

feeding HCP Contact Survey & participation Workshop on B/R in scientific communication advice





# Pharmacovigilance: from monitoring to safer use

RMP ADR Eudra summaries reporting vigilance

Additional monitoring Risk
Nitrosamines Black management
Medication triangle PRISMA

errors Impact

Public HCPWP topic DHCPs group on review hearings RMMs EU

Off-label use Falsified legislation medicines





## Clinical trials: collaboration for better medicines

Joint ICH trials Decentralised drafting group EU legislation trials proup trials

ICH GCP E6 E8 Multi Clinical stakeholder platform trial

# **ACT EU** transparency

data paediatric Workshop on CTR clinical registry based EU CT portal research studies





## Medicines shortages: working together is key

**EU** Shortages reporting **guidance** on by organisations shortage prevention pilot

Pandemic response EMA-HMA & shortages Task Force

Guidance for public Multiauthorities on stakeholder communication workshops

**HCP-POs** common position





# Digital transformation: ongoing (r)evolution

collaboration on patient mHealth Pilot registries **Big Data** Patient Secondary use of data Steering experience data Topic group Group RWD digital media **EHDS** Data protection **DARWIN EU GDPR ERN** model workshop **Data analytics** in EHDS RWE Data anonymisation workshop





# COVID-19 pandemic: importance of dialogue

**Communication**Public health Combating COVID-19 messages misinfor Vaccines safety updates Vaccines safety Vaccine confidence **HCPs on Transparency EMA ETF Public stakeholder** Therapeutics meetings





## Biosimilar medicines: from "new" to "normal"

**EMA Guide EMA** for HCPs biosimilars Biosimilars action plan **EMA** and shortages biosimilars communi Interchangeability cation plan **EMA/HMA statement Biosimilars WG Information** meeting with **EC** session stakeholders stakeholder workshops





# Antimicrobial resistance: an emerging priority

**Information Stakeholder** session European survey on AMR Antibiotic **ECDC survey Awareness** on HCP Day EMA messages perceptions for **EAAD** multi stakeholder workshop in pipeline





## Innovation & access to medicines

implications of Workshop on innovation for approval challenges clinical practice for immunotherapies

PRIME EMA-HTA interface

adaptive ATMPs Personalised medicine pilot Repurposing Adapt
10 years report EUNetHTA Smart conditional MA





## Governance and strategy: HCPWP input

Multistakeholder engagement

Workshop on Strategy to 2020 criteria

**EMA** extended

mandate EMA Network Collaboration

Workshop: Strategy to 2025: with GPs

EMA 25 years early engagement

HCPWP topic

Regulatory Science to group on 2025 multistakeholder academia workshop Framework on

Regulatory collaboration with science research academia Policy on

agenda Transparency





## HCPs on EMA committees & advisory boards

#### **EMA MB**

Wolf-Dieter Ludwig Denis Lacombe

#### **PDCO**

Johannes Timaniau

#### **COMP**

Katerina Kubackova Daniel O'Connor Elisabeth Johanne Rook

#### **HMPC**

Steffen Bager Olga Maria Palomino

#### **CHMP**

Dinah Duarte Fatima Ventura

#### **CAT**

Olli Tenhunen Bernd Gansbacher Alessandro Aiuti

#### **PRAC**

Kirsten Mhyr Filip Babylon Jane Ahlqvist-Rastad Raymond Anderson Roberto Frontini



### **Big Data Steering Group**

Ioanna Agache

## **DARWIN EU Advisory Board**

Aldo Maggioni

#### **EMA Emergency Task Force**

Anita Simonds Tiago Villanueva

## **HCP** and **EMA** co-chairs



Gonzalo Calvo



Ulrich Jaeger



Rosa Giuliani



Isabelle Moulon



Juan García Burgos

## The HCPWP Secretariat



Ivana Silva



Zhenya Shtereva



Kaisa Immonen



Nicola Martin



Malika Holleyman

# YEARS HCPWP